Skylands Capital LLC Grows Stock Holdings in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Skylands Capital LLC lifted its stake in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 19.7% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 156,790 shares of the company’s stock after buying an additional 25,815 shares during the period. GE HealthCare Technologies comprises about 1.7% of Skylands Capital LLC’s holdings, making the stock its 16th largest position. Skylands Capital LLC’s holdings in GE HealthCare Technologies were worth $12,258,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of GEHC. IFP Advisors Inc lifted its stake in shares of GE HealthCare Technologies by 15.1% in the fourth quarter. IFP Advisors Inc now owns 2,743 shares of the company’s stock worth $215,000 after buying an additional 360 shares in the last quarter. Waverton Investment Management Ltd purchased a new stake in GE HealthCare Technologies during the fourth quarter valued at approximately $48,977,000. Union Bancaire Privee UBP SA purchased a new stake in GE HealthCare Technologies during the fourth quarter valued at approximately $280,000. MONECO Advisors LLC purchased a new stake in GE HealthCare Technologies during the fourth quarter valued at approximately $245,000. Finally, Howard Capital Management Inc. increased its stake in shares of GE HealthCare Technologies by 3.0% in the fourth quarter. Howard Capital Management Inc. now owns 10,681 shares of the company’s stock worth $835,000 after purchasing an additional 313 shares in the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on GEHC. Jefferies Financial Group raised shares of GE HealthCare Technologies from a “hold” rating to a “buy” rating and increased their price objective for the stock from $95.00 to $103.00 in a research note on Wednesday, January 8th. Wells Fargo & Company increased their price objective on shares of GE HealthCare Technologies from $96.00 to $103.00 and gave the company an “overweight” rating in a research report on Friday, February 14th. Finally, Citigroup raised their target price on shares of GE HealthCare Technologies from $103.00 to $110.00 and gave the stock a “buy” rating in a report on Thursday, February 13th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $97.67.

GE HealthCare Technologies Trading Down 1.1 %

NASDAQ GEHC opened at $91.09 on Monday. The firm’s 50-day moving average is $85.05 and its two-hundred day moving average is $85.90. GE HealthCare Technologies Inc. has a 12 month low of $74.51 and a 12 month high of $94.80. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.04 and a quick ratio of 0.83. The stock has a market capitalization of $41.66 billion, a P/E ratio of 21.04, a PEG ratio of 3.19 and a beta of 1.15.

GE HealthCare Technologies (NASDAQ:GEHC) last issued its quarterly earnings results on Thursday, February 13th. The company reported $1.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.26 by $0.19. GE HealthCare Technologies had a net margin of 10.13% and a return on equity of 25.74%. The business had revenue of $5.32 billion for the quarter, compared to analysts’ expectations of $5.33 billion. On average, sell-side analysts anticipate that GE HealthCare Technologies Inc. will post 4.68 earnings per share for the current year.

GE HealthCare Technologies Company Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.